Actively Recruiting

Phase 1
Age: 18Years - 100Years
All Genders
NCT05783622

Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies

Led by Janux Therapeutics · Updated on 2025-10-14

130

Participants Needed

18

Research Sites

232 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This study is a first-in-human (FIH), Phase 1/1b, open-label, multicenter dose escalation and dose expansion study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of JANX008 in adult subjects with advanced or metastatic carcinoma expressing EGFR.

CONDITIONS

Official Title

Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies

Who Can Participate

Age: 18Years - 100Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Subjects 18 years of age or older at the time of signing informed consent
  • Diagnosis of locally advanced or metastatic non-small cell lung cancer, squamous cell carcinoma of the head and neck, colorectal carcinoma, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, or triple-negative breast cancer
  • Disease has progressed or patient is intolerant to all available therapies known to benefit their tumor type
  • Adequate organ function
  • At least one measurable tumor lesion according to RECIST 1.1 criteria
Not Eligible

You will not qualify if you...

  • Received anti-cancer therapy within 28 days or 5 elimination half-lives, whichever is earlier, before enrollment
  • Prior treatment with EGFR-targeted bispecific T cell engager or CAR-T cell therapy
  • Prior treatment with CD3 engaging bispecific antibodies
  • Presence of clinically significant cardiovascular diseases
  • Active clinically significant infections including bacterial, viral, fungal, or mycobacterial
  • Currently on supplemental oxygen
  • Any medical condition or abnormal clinical laboratory results that could interfere with safety or efficacy assessment of the study treatment

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 18 locations

1

City of Hope Medical Center

Duarte, California, United States, 91010

Actively Recruiting

2

University of California, Davis Comprehensive Cancer Center

Sacramento, California, United States, 95817

Actively Recruiting

3

University of California San Diego Moores Cancer Center

San Diego, California, United States, 92093

Actively Recruiting

4

Winship Cancer Institute, Emory University

Atlanta, Georgia, United States, 30308

Actively Recruiting

5

University of Chicago Medical Center

Chicago, Illinois, United States, 60637

Actively Recruiting

6

University of Michigan

Ann Arbor, Michigan, United States, 48109

Actively Recruiting

7

Henry Ford Health System

Detroit, Michigan, United States, 48202

Actively Recruiting

8

Washington University

St Louis, Missouri, United States, 63110

Actively Recruiting

9

Laura and Isaac Perlmutter Cancer Center NYU Langone Health

New York, New York, United States, 10016

Actively Recruiting

10

University of North Carolina at Chapel Hill

Chapel Hill, North Carolina, United States, 27599

Actively Recruiting

11

The Christ Hospital Cancer Center

Cincinnati, Ohio, United States, 45219

Actively Recruiting

12

Ohio State University Hospital

Columbus, Ohio, United States, 43210

Actively Recruiting

13

University of Pennsylvania, Abramson Cancer Center

Philadelphia, Pennsylvania, United States, 19104

Actively Recruiting

14

UPMC Hillman Cancer Center

Pittsburgh, Pennsylvania, United States, 15232

Actively Recruiting

15

Rhode Island Hospital

Providence, Rhode Island, United States, 02903

Actively Recruiting

16

Sarah Cannon Research Institute

Nashville, Tennessee, United States, 37203

Actively Recruiting

17

University of Texas Southwestern Medical Center

Dallas, Texas, United States, 75390

Actively Recruiting

18

The University of Texas, MD Anderson Cancer Center

Houston, Texas, United States, 77030

Actively Recruiting

Loading map...

Research Team

J

Janux Therapeutics

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

SEQUENTIAL

Primary Purpose

TREATMENT

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies | DecenTrialz